Clinical Trial

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Name: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer — clinical trial record (NCT07415005)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-06

Trial Details

NCT Number	NCT07415005
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Advanced Non-Small Cell Lung Cancer
Enrollment	30 participants
Start Date	2026-04-24
Primary Completion	2028-07-22 (estimated)
Study Completion	2030-07-22 (estimated)
Updated on ClinicalTrials.gov	2026-05-05